ResoTher Pharma is pleased to announce that we have completed IND-enabling toxicology studies of the lead drug RTP-026. The studies have been carried out in collaboration with Charles River Labs and Merck Bioreliance, both leading global providers of GLP-certified preclinical research services. The next stage of development will focus on demonstrating suitable safety and tolerability in humans. The phase I clinical studies are scheduled for commencement in 2021.
ResoTher Pharma R&D update
|Published on: Nov 20, 2020||